Bloque 1
Lottspeich F,Kellermann J,Keidel EM. Molecular biology tools: proteomics techniques in biomarkerdiscovery.Scand J Clin Lab Invest Suppl.2010;242:19-22. doi: 10.3109/00365513.2010.493359.
Vathany Kulasingam and Eleftherios P Diamandis.Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Clinical Practice Oncology (2008) 5, 588-599 doi:10.1038/ncponc1187
Juan A Marchal; Gabriel J Lopez; Macarena Peran; Ana Comino; Juan R Delgado; Javier A García García;Veronica Conde; Fernando M Aranda; Carmen Rivas; Mariano Esteban; Maria A Garcia. The impact of PKR activation: from neurodegeneration to cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 28 - 5, pp. 1965 - 2039. 05/2014. ISSN 1530-6860
Juan Antonio Marchal; Esther Carrasco; Alberto Ramirez; Gema Jiménez; Carmen Olmedo; Macarena Peran; Ahmad Agil; Ana Conejo García; Olga Cruz López; Joaquin María Campos; María Ángel García. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFN# triggering apoptosis, autophagy and senescence.Drug design, development and therapy. 7, pp. 1301 - 1314. (Nueva Zelanda): 2013.ISSN 1177-8881
María Angel García; Esther Carrasco; Margarita Aguilera; Pablo Alvarez; Carmen Rivas; Joaquin María Campos;Jose Carlos Prados; Miguel Angel Calleja; Mariano Esteban; Juan Antonio Marchal; Antonia Aránega. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PloS One. 6 - 8, pp. e23887. 2011. ISSN 1932-6203
Nadal R, Lorente JA, Rosell R, Serrano MJ.Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies.Expert Rev Mol Diagn. 2013 Apr;13(3):295-307.
Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, Delgado-Rodriguez M, Solé F, García MA, Perán M, Rosell R, Marchal JA, Lorente JA.EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.Oncotarget. 2014 Sep 15;5(17):7486-97.
Ortega FG, Lorente JA, Garcia Puche JL, Ruiz MP, Sanchez-Martin RM, de Miguel-Pérez D, Diaz-Mochon JJ, Serrano MJ.miRNA in situ hybridization in circulating tumor cells--MishCTC.Sci Rep. 2015 Mar 17;5:9207.
Dormant Circulating Tumor Cells In Prostate Cancer: Biological, Clinical And Therapeutic Implications.
Alvarez-Cubero MJ, Vázquez-Alonso F, Puche-Sanz I, Ortega FG, Martin-Prieto M, Garcia-Puche JL, Pascual-Geler M, Lorente JA, Cozar-Olmo JM,Serrano MJ. Curr Drug Targets. 2015 Mar 9.
Bloque 2
1. Laura G. Pedraza-Fariña. Mechanisms of Oncogenic Cooperation in Cancer Initiation and Metastasis. Yale J Biol Med. 2006 Dec; 79(3-4): 95–103.
2. Knudson AG., Jr. Mutation and cancer: statistical study of retinoblastoma.Proceedings of the National Academy of Sciences of the United States of America. 1971;68(4):820–823.
3. Roshan Fatima, Vijay Suresh Akhade, Debosree Pal, and Satyanarayana MR. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015; 3: 5.
4. Marilena V Iorio and Carlo M Croce. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012 Mar; 4(3): 143–159.
5. Yannick Delpu, Pierre Cordelier William C. Cho, and Jérôme Torrisani. DNA Methylation and Cancer Diagnosis. Int J Mol Sci. 2013 Jul; 14(7): 15029–15058.
6. William A. Freed-Pastor and Carol Prives. Mutant p53: one name, many proteins
Genes Dev. 2012 Jun 15; 26(12): 1268–1286.
7. Gemma Binefa, Francisco Rodríguez-Moranta, Àlex Teule, and Manuel Medina-Hayas. Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol. 2014 Jun 14; 20(22): 6786–6808.
8. R Fernández-Ramires, X Solé, L De Cecco, G Llort, A Cazorla, N Bonifaci, M J Garcia, T Caldés, I Blanco, M Gariboldi, M A Pierotti, M A Pujana,* J Benítez, and A Osorio. Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. Br J Cancer. 2009 Oct 20; 101(8): 1469–1480.
9. Hensin Tsao, Lynda Chin, Levi A. Garraway, and David E. Fisher. Melanoma: from mutations to medicine. Genes Dev. 2012 Jun 1; 26(11): 1131–1155.
10. qbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM,Wang C, Rohr J, Guo S, Smith LM, Wright G, Bhagavathi S, Dybkaer K, Fu K, GreinerTC, Vose JM, Jaffe E, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, BrazielRM, Cook JR, Tubbs RR, Armitage JO, eisenburger DD, Staudt LM, Gascoyne RD,McKeithan TW, Chan WC. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015 Feb 12;125(7):1137-45.
Bloque 3
Kina H-glundab; Hugh Salter. Molecular biomarkers of neurodegeneration. Expert Review of Molecular Diagnostics 2013; 13: 845-861.
Diane B. Miller, James P. O-Callaghan. Biomarkers of Parkinson-s disease: Present and future. Metabolism. Clinical and Experimental 2015; 64:  S40-S46.
Brit Mollenhauer; Jing Zhang. Biochemical Pre-motor Biomarkers for Parkinson Disease. Movement Disorders 2012; 27 (5):644-650.
Sushil Sharmaa, Carolyn Seungyoun Moona, Azza Khogalia, Ali Haidousa, Anthony Chabennea, Comfort Ojoa,
Miriana Jelebinkova, Yousef Kurdia, Manuchair Ebadi. Biomarkers in Parkinson-s disease (recent update). Neurochemistry International 2015; 63: 201-229.
Vincenzo Bonifati. Genetics of Parkinson's disease - state of the art, 2013. Parkinsonism and Related Disorders 2014; 20: S23-S28.
Suzanne Lesage, Alexis Brice. Parkinson-s disease: from monogenic forms to genetic susceptibility factors. Hum   Mol Genet 2009; 18: R48-R59.
